Secondary interventions following open versus endovascular revascularization for chronic limb threatening ischemia in the BEST-CLI trial.

chronic limb threatening ischemia critical limb ischemia endovascular lower extremity bypass peripheral artery disease revascularization

Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
16 Feb 2024
Historique:
received: 28 11 2023
revised: 02 02 2024
accepted: 11 02 2024
medline: 19 2 2024
pubmed: 19 2 2024
entrez: 18 2 2024
Statut: aheadofprint

Résumé

Patients undergoing revascularization for CLTI experience a high burden of target limb re-interventions. We analyzed data from the BEST-CLI randomized trial comparing initial open bypass (OPEN) and endovascular (ENDO) treatment strategies, with a focus on re-intervention related study endpoints. In a planned secondary analysis we examined the rates of major re-intervention, any re-intervention, and the composite of any re-intervention, amputation or death (RAD) by intention-to-treat (ITT) assignment in both trial cohorts (cohort 1 with suitable single segment great saphenous vein [SSGSV], N=1434; cohort 2 lacking suitable SSGSV, N= 396). We also compared the cumulative number of major and all index limb re-interventions over time. Comparisons between treatment arms within each cohort were made using univariable and multivariable Cox regression models. In cohort 1, assignment to OPEN was associated with a significantly reduced hazard of a major limb re-intervention (HR [95% CI]: 0.37 [0.28,0.49], p<0.001), any re-intervention (HR: 0.63 [0.53, 0.75], p<.001), or RAD (HR: 0.68 [0.60-0.78], p<.001). Findings were similar in cohort 2 for major re-intervention (HR: 0.53 [0.33,0.84], p=.007) or any re-intervention (HR: 0.71 [0.52, 0.98], p=.04). In both cohorts, early (30-day) limb re-interventions were notably higher for patients assigned to ENDO as compared to OPEN (14.7% vs 4.5% of cohort 1 subjects; 16.6% vs 5.6% of cohort 2 subjects). The mean number of major (mean events per subject ratio (MR) 0.45 [95% CI: 0.34, 0.58], p < 0.001) or any target limb re-interventions (MR 0.67 [0.57, 0.80], p < 0.001) per year was significantly less in the OPEN arm of cohort 1. The mean number of re-interventions per limb salvaged per year was lower in the OPEN arm of cohort 1 (MR 0.45 [0.35, 0.57], p <.001 and MR 0.66 [0.55, 0.79], p <.001 for major and all, respectively). The majority of index limb re-interventions occurred during the first year following randomization, but events continued to accumulate over the duration of follow-up in the trial. Reintervention is common following revascularization for CLTI. Among patients deemed suitable for either approach, initial treatment with open bypass, particularly in patients with available SSGSV conduit, is associated with a significantly lower number of major and minor target limb reinterventions.

Identifiants

pubmed: 38368997
pii: S0741-5214(24)00308-2
doi: 10.1016/j.jvs.2024.02.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Michael S Conte (MS)

Division of Vascular and Endovascular Surgery, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Michael.conte2@ucsf.edu.

Ezana Azene (E)

Department of Interventional Radiology, Gundersen Health System, La Crosse, WI, USA.

Gheorghe Doros (G)

Boston University School of Public Health, Boston, MA, USA.

Warren J Gasper (WJ)

Division of Vascular and Endovascular Surgery, University of California, San Francisco, San Francisco, CA, USA.

Taye Hamza (T)

HealthCore, Inc, Watertown, MA, USA.

Vikram S Kashyap (VS)

Frederik Meijer Heart and Vascular Institute, Corewell Health, Grand Rapids MI.

Randy Guzman (R)

Section of Vascular Surgery, Hospital St. Boniface, Winnipeg, MB, Canada.

Carlos Mena-Hurtado (C)

Vascular Medicine Outcomes Program, Yale University, New Haven, CT.

Matthew T Menard (MT)

Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Kenneth Rosenfield (K)

Section of Vascular Medicine and Intervention Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Vincent L Rowe (VL)

Division of Vascular Surgery and Endovascular Therapy, University of California, Los Angeles, CA.

Michael Strong (M)

Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Alik Farber (A)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.

Classifications MeSH